{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:00:32Z","timestamp":1771657232065,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Braz J Microbiol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s42770-019-00200-4","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:02:46Z","timestamp":1576504966000},"page":"169-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium"],"prefix":"10.1007","volume":"51","author":[{"given":"Bruna Kochhann","family":"Menezes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabel Almeida","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keli Jaqueline","family":"Staudt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betina Montanari","family":"Beltrame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia","family":"Venz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lessandra","family":"Michelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana Verlindo","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-9204","authenticated-orcid":false,"given":"Leandro","family":"Tasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"200_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000109868","volume":"81","author":"R Sauermann","year":"2008","unstructured":"Sauermann R, Rothernburger M, Graninger W (2008) Daptomycin: a review 4 years after first approval. Pharmacology. 81:79\u201391","journal-title":"Pharmacology."},{"key":"200_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/2047-783X-15-12-533","volume":"15","author":"KS Estes","year":"2010","unstructured":"Estes KS, Derendorf H (2010) Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecycline, and daptomycin. Eur J Med Res 15:533\u2013543","journal-title":"Eur J Med Res"},{"key":"200_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jac\/dkm170","volume":"60","author":"ER Rose","year":"2007","unstructured":"Rose ER, Rybak MJ, Kaatz GW (2007) Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60:334\u2013340","journal-title":"J Antimicrob Chemother"},{"key":"200_CR4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38:1673\u20131681","journal-title":"Clin Infect Dis"},{"key":"200_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1128\/CMR.00002-14","volume":"27","author":"KB Laupland","year":"2014","unstructured":"Laupland KB, Deirdre LC (2014) Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 27:647\u2013664","journal-title":"Clin Microbiol Rev"},{"key":"200_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"DM Sievert","year":"2013","unstructured":"Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A et al (2013) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010. Infect Control Hosp Epidemiol 34:1\u201314","journal-title":"Infect Control Hosp Epidemiol"},{"key":"200_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrmicro2761","volume":"10","author":"CA Arias","year":"2012","unstructured":"Arias CA, Murray BE (2012) The rise of the enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 10:266\u2013278","journal-title":"Nat Rev Microbiol"},{"key":"200_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.diagmicrobio.2013.10.008","volume":"78","author":"RN Jones","year":"2014","unstructured":"Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M (2014) Resistance surveillance program report for selected European nations: 2011. Diagn Microbiol Infect Dis 78:429\u2013436","journal-title":"Diagn Microbiol Infect Dis"},{"key":"200_CR9","first-page":"217","volume":"8","author":"T O\u2019Driscoll","year":"2015","unstructured":"O\u2019Driscoll T, Crank CW (2015) Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 8:217\u2013230","journal-title":"Infect Drug Resist"},{"key":"200_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/jac\/dkq087","volume":"65","author":"R Canton","year":"2010","unstructured":"Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP (2010) A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 65:1126\u20131136","journal-title":"J Antimicrob Chemother"},{"key":"200_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ddtec.2016.08.004","volume":"21\u201322","author":"C Rathi","year":"2016","unstructured":"Rathi C, Lee RE, Meibohm B (2016) Translational PK\/PD of anti-infective therapeutics. Drug Discov Today Technol 21\u201322:41\u201349","journal-title":"Drug Discov Today Technol"},{"key":"200_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3109\/23744235.2015.1064542","volume":"47","author":"C Wei","year":"2015","unstructured":"Wei C, Ni W, Cai X, Cui J (2015) A Monte Carlo pharmacokinetic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin and levofloxacin in the treatment of hospital-acquired pneumonia causes by Stenotrophomonas maltophila. Infect Dis (Lond) 47:846\u2013851","journal-title":"Infect Dis (Lond)"},{"key":"200_CR13","volume-title":"CLSI document M100-S27","author":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty fourth informational supplement","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty fourth informational supplement (2017) CLSI document M100-S27. Wayne, Pennsylvania"},{"key":"200_CR14","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/pr.111.005769","volume":"65","author":"EI Nielsen","year":"2013","unstructured":"Nielsen EI, Friberg LE (2013) Pharmacokinetics-pharmacodynamics modeling of antibacterial drugs. Pharmacol Rev 65:1053\u20131090","journal-title":"Pharmacol Rev"},{"key":"200_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ijantimicag.2013.06.006","volume":"42","author":"A Di Paolo","year":"2013","unstructured":"Di Paolo A, Tascini C, Polollo M, Gemignani G, Nielsen EI, Bocci G et al (2013) Population pharmacokinetics of daptomycin in patients affected by severe gram-positive infections. Int J Antimicrob Agents 42:250\u2013255","journal-title":"Int J Antimicrob Agents"},{"key":"200_CR16","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1128\/AAC.00247-06","volume":"50","author":"M Benvenuto","year":"2006","unstructured":"Benvenuto M, Benziger DP, Yankelev S, Vigliani G (2006) Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50:3245\u20133249","journal-title":"Antimicrob Agents Chemother"},{"key":"200_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2217\/17460913.1.3.255","volume":"1","author":"A Johnson","year":"2006","unstructured":"Johnson A (2006) Daptomycin in the treatment of skin, soft-tissue and invasive infections due to gram-positive bacteria. Future Microbiol 1:255\u2013265","journal-title":"Future Microbiol"},{"key":"200_CR18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/9780470376980.ch40","volume-title":"Biology, medicine and surgery of South American wild animals","author":"JR Pachaly","year":"2001","unstructured":"Pachaly JR, Fernando H, De Brito V (2001) Interspecific allometric scaling. In: Murray E, Fowler DVM (eds) Biology, medicine and surgery of South American wild animals. Iowa State University Press, Ames, Iowa, pp 475\u2013481"},{"key":"200_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1369-5274(00)00132-6","volume":"3","author":"MN Dudley","year":"2000","unstructured":"Dudley MN, Ambrose PG (2000) Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol 3:515\u2013521","journal-title":"Curr Opin Microbiol"},{"key":"200_CR20","unstructured":"EUCAST. 2017. Available at: http:\/\/www.eucast.org\/clinical_breakpoints\/ (last accessed 15 May 2019)."},{"key":"200_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijantimicag.2006.08.049","volume":"29","author":"W Treyaprasert","year":"2007","unstructured":"Treyaprasert W, Schmidt S, Rand KH, Suvanakoot U, Derendorf H (2007) Pharmacokinetic\/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents 29:263\u2013270","journal-title":"Int J Antimicrob Agents"},{"key":"200_CR22","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/jac\/dkx140","volume":"72","author":"PG Cojutti","year":"2017","unstructured":"Cojutti PG, Candoni A, Ramos-Martin V, Lazzarotto D, Zannier ME, Fanin R et al (2017) Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. J Antimicrob Chemother 72:2342\u20132350","journal-title":"J Antimicrob Chemother"},{"key":"200_CR23","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/jac\/dkr255","volume":"66","author":"EA King","year":"2011","unstructured":"King EA, MaCoy D, Desai S, Nvirenda T, Bicking K (2011) Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother 66:2112\u20132118","journal-title":"J Antimicrob Chemother"},{"key":"200_CR24","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1093\/cid\/ciw173","volume":"62","author":"BS Shukla","year":"2016","unstructured":"Shukla BS, Shelbume S, Reyes K, Kamboi M, Lewis JD, Ricon SL et al (2016) Influence of minimum inhibitory concentration of outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint? Clin Infect Dis 62:1514\u20131520","journal-title":"Clin Infect Dis"},{"key":"200_CR25","first-page":"e00506","volume":"24","author":"JM Kidd","year":"2018","unstructured":"Kidd JM, Abdelraouf K, Asempa TE, Humphries RM, Nicolau DP (2018) Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the murine thigh infection model. Antimicrob Agents Chemother 24:e00506\u2013e00518","journal-title":"Antimicrob Agents Chemother"},{"key":"200_CR26","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.clinthera.2016.09.011","volume":"38","author":"PP Chong","year":"2016","unstructured":"Chong PP, Duin DV, Bangdiwala A, Ivanova A, Miller WC, Weber DJ et al (2016) Vancomycin-resistant enterococcal bloodstream infections in hematopoietic stem cell transplant recipients and patients with hematologic malignancies: impact of daptomycin MICs of 3 to 4 mg\/L. Clin Ther 38:2468\u20132476","journal-title":"Clin Ther"},{"issue":"5","key":"200_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2005) Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55(5):601\u2013607","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"200_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10928-007-9069-x","volume":"34","author":"D Czock","year":"2007","unstructured":"Czock D, Keller F (2007) Mechanism-based pharmacokinetic\u2013pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 34(6):727\u2013751","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"10","key":"200_CR29","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1128\/AAC.00182-11","volume":"55","author":"EI Nielsen","year":"2011","unstructured":"Nielsen EI, Cars O, Friberg LE (2011 Oct) Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 55(10):4619\u20134630","journal-title":"Antimicrob Agents Chemother"},{"key":"200_CR30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/cid\/cix024","volume":"64","author":"YC Chuang","year":"2017","unstructured":"Chuang YC, Lin HY, Chen CY, Lin CY, Wang JT, Chen YC et al (2017) Effect of Daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia. Clin Infect Dis 64:1026\u20131034","journal-title":"Clin Infect Dis"},{"issue":"7","key":"200_CR31","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1345\/aph.1M085","volume":"43","author":"PA Moise","year":"2009","unstructured":"Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC (2009) Safety and clinical outcomes when utilizing high-dose (> or =8 mg\/kg) daptomycin therapy. Ann Pharmacother 43(7):1211\u20131219","journal-title":"Ann Pharmacother"},{"issue":"12","key":"200_CR32","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","volume":"32","author":"RA Seaton","year":"2015","unstructured":"Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K (2015) Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin\u00ae. Outcomes Registry and Experience. Adv Ther 32(12):1192\u20131205","journal-title":"Adv Ther"},{"issue":"11","key":"200_CR33","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1128\/AAC.00038-12","volume":"56","author":"I Byren","year":"2012","unstructured":"Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, Evans R (2012) Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 56(11):5626\u20135632","journal-title":"Antimicrob Agents Chemother"},{"key":"200_CR34","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1128\/AAC.00526-13","volume":"57","author":"AM Casapao","year":"2013","unstructured":"Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA et al (2013) Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother 57:4190\u20134196","journal-title":"Antimicrob Agents Chemother"},{"key":"200_CR35","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.clinthera.2010.09.008","volume":"32","author":"CW Crank","year":"2010","unstructured":"Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, Segreti J (2010) Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infections: a retrospective, multicenter, cohort study. Clin Ther 32:1713\u20131719","journal-title":"Clin Ther"},{"key":"200_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijantimicag.2013.05.005","volume":"42","author":"IM Gould","year":"2013","unstructured":"Gould IM, Mir\u00f3 JM, Rybak MJ (2013) Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 42:202\u2013210","journal-title":"Int J Antimicrob Agents"}],"container-title":["Brazilian Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-019-00200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s42770-019-00200-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-019-00200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T02:32:25Z","timestamp":1695522745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s42770-019-00200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1007\/s42770-019-00200-4","relation":{},"ISSN":["1517-8382","1678-4405"],"issn-type":[{"value":"1517-8382","type":"print"},{"value":"1678-4405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"26 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}